Loading clinical trials...
Loading clinical trials...
Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors
Conditions
Interventions
Nintedanib
Bevacizumab
Locations
1
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
Start Date
June 9, 2016
Primary Completion Date
April 14, 2018
Completion Date
June 14, 2018
Last Updated
July 10, 2018
NCT07227402
NCT02600949
NCT05969860
NCT04693377
NCT07117227
NCT05969496
Lead Sponsor
University of Alabama at Birmingham
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions